Flavia M. Facio
Research Subjects
Flavia M. Facio has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amy Cronister
Integrated Genetics Dushore PA USA
1 shared publication - Campbell K. Brasington
Levine Children's Hospital at Carolinas Medical Center Charlotte NC USA
1 shared publication Julianne M. O'DAniel
Department of Genetics University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA
1 shared publication- Kelly E. Ormond
Department of Genetics Stanford University School of Medicine Stanford California USA
1 shared publication - Kristy Lee
University of North Carolina at Chapel Hill
1 shared publication - Pamela Flodman
Division of Genetics and Metabolism, Department of Pediatrics University of California Irvine CA USA
1 shared publication
Latest Publications
- Open Access
- 24 October 2013
- Published by Wiley in Journal of Genetic Counseling
- Vol. 23 (4) , 455-462
A Genetic Counselor's Guide to Using Next‐Generation Sequencing in Clinical Practice
Advances in next‐generation sequencing (NGS) and rapid reductions in cost have increased the use of such technologies in research and clinical practice. However, many barriers exist to translating NGS for routine clinical use, including issues related to the interpretation of results, and the potential to find results that are secondary or incidental to the specific application of NGS. Nonetheless, NGS has become sufficiently affordable to be offered by several clinical laboratories, and increasingly it is becoming an attractive and viable option for clinicians and patients. This article reviews current NGS technologies, highlighting the information genetic counselors need to know to make informed‐decisions about utilizing NGS in the clinic, and underscoring the impact of this new testing modality on the practice of genetic counseling.
- 24 October 2013
- Published by Wiley in Journal of Genetic Counseling
- Vol. 23 (4) , 455-462
Open AccessA Genetic Counselor's Guide to Using Next‐Generation Sequencing in Clinical Practice
Advances in next‐generation sequencing (NGS) and rapid reductions in cost have increased the use of such technologies in research and clinical practice. However, many barriers exist to translating NGS for routine clinical use, including issues related to the interpretation of results, and the potential to find results that are secondary or incidental to the specific application of NGS. Nonetheless, NGS has become sufficiently affordable to be offered by several clinical laboratories, and increasingly it is becoming an attractive and viable option for clinicians and patients. This article reviews current NGS technologies, highlighting the information genetic counselors need to know to make informed‐decisions about utilizing NGS in the clinic, and underscoring the impact of this new testing modality on the practice of genetic counseling.
- Open Access
- 22 January 2013
- Published by Wiley in Journal of Genetic Counseling
- Vol. 22 (3) , 291-295
Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis: the Position of the National Society of Genetic Counselors
The 1997 discovery of free fetal DNA in maternal plasma launched clinical researchers’ efforts to establish a reliable method for non‐invasive prenatal testing for fetal genetic conditions. Various methods, including, but not limited to, massively parallel sequencing (MPS) and selective analysis of cell‐free fetal DNA in maternal plasma, have recently been developed as highly sensitive and specific noninvasive screening tools for common fetal chromosome aneuploidies. Incorporating these new noninvasive technologies into clinical practice will impact the current prenatal screening paradigm for fetal aneuploidy, in which genetic counseling plays an integral role. The National Society of Genetic Counselors (NSGC) currently supports Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis (NIPT/NIPD) as an option for patients whose pregnancies are considered to be at an increased risk for certain chromosome abnormalities. NSGC urges that NIPT/NIPD only be offered in the context of informed consent, education, and counseling by a qualified provider, such as a certified genetic counselor. Patients whose NIPT/NIPD results are abnormal, or who have other factors suggestive of a chromosome abnormality, should receive genetic counseling and be given the option of standard confirmatory diagnostic testing.
- 22 January 2013
- Published by Wiley in Journal of Genetic Counseling
- Vol. 22 (3) , 291-295
Open AccessNoninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis: the Position of the National Society of Genetic Counselors
The 1997 discovery of free fetal DNA in maternal plasma launched clinical researchers’ efforts to establish a reliable method for non‐invasive prenatal testing for fetal genetic conditions. Various methods, including, but not limited to, massively parallel sequencing (MPS) and selective analysis of cell‐free fetal DNA in maternal plasma, have recently been developed as highly sensitive and specific noninvasive screening tools for common fetal chromosome aneuploidies. Incorporating these new noninvasive technologies into clinical practice will impact the current prenatal screening paradigm for fetal aneuploidy, in which genetic counseling plays an integral role. The National Society of Genetic Counselors (NSGC) currently supports Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis (NIPT/NIPD) as an option for patients whose pregnancies are considered to be at an increased risk for certain chromosome abnormalities. NSGC urges that NIPT/NIPD only be offered in the context of informed consent, education, and counseling by a qualified provider, such as a certified genetic counselor. Patients whose NIPT/NIPD results are abnormal, or who have other factors suggestive of a chromosome abnormality, should receive genetic counseling and be given the option of standard confirmatory diagnostic testing.